Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Biochem Pharmacol ; 106: 56-69, 2016 Apr 15.
Article in English | MEDLINE | ID: mdl-26883061

ABSTRACT

Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110α and p110δ class IA PI3K. Whereas the functioning of PI3K p110δ in immune and autoimmune reactions is well established, the role of p110α is less well understood. Here, a novel dual p110α/δ inhibitor (ETP-46321) and highly specific p110α (A66) or p110δ (IC87114) inhibitors have been compared concerning T cell activation in vitro, as well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. In vitro activation of naive CD4(+) T lymphocytes by anti-CD3 and anti-CD28 was inhibited more effectively by the p110δ inhibitor than by the p110α inhibitor as measured by cytokine secretion (IL-2, IL-10, and IFN-γ), T-bet expression and NFAT activation. In activated CD4(+) T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-γ better than A66. The p110α/δ inhibitor ETP-46321, or p110α plus p110δ inhibitors also inhibited IL-21 secretion by differentiated CD4(+) T follicular (Tfh) or IL-17-producing (Th17) helper cells. In vivo, therapeutic administration of ETP-46321 significantly inhibited responses to protein antigen as well as collagen-induced arthritis, as measured by antigen-specific antibody responses, secretion of IL-10, IL-17A or IFN-γ, or clinical symptoms. Hence, p110α as well as p110δ Class IA PI3Ks are important to immune regulation; inhibition of both subunits may be an effective therapeutic approach in inflammatory autoimmune diseases like rheumatoid arthritis.


Subject(s)
Arthritis, Experimental/drug therapy , CD4-Positive T-Lymphocytes/drug effects , Enzyme Inhibitors/pharmacology , Imidazoles/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Protein Subunits/antagonists & inhibitors , Pyrazines/pharmacology , Animals , Antibodies/pharmacology , Arthritis, Experimental/enzymology , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , CD28 Antigens/genetics , CD28 Antigens/immunology , CD3 Complex/genetics , CD3 Complex/immunology , CD4-Positive T-Lymphocytes/enzymology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , Class Ia Phosphatidylinositol 3-Kinase/genetics , Class Ia Phosphatidylinositol 3-Kinase/immunology , Extracellular Signal-Regulated MAP Kinases/genetics , Extracellular Signal-Regulated MAP Kinases/immunology , Gene Expression , Interferon-gamma/genetics , Interferon-gamma/immunology , Interleukin-10/genetics , Interleukin-10/immunology , Interleukin-2/genetics , Interleukin-2/immunology , Lymph Nodes/drug effects , Lymph Nodes/enzymology , Lymph Nodes/immunology , Lymph Nodes/pathology , Lymphocyte Activation/drug effects , Mice , Mice, Inbred C57BL , NFATC Transcription Factors/genetics , NFATC Transcription Factors/immunology , Protein Subunits/genetics , Protein Subunits/immunology , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/immunology , T-Box Domain Proteins/genetics , T-Box Domain Proteins/immunology
2.
Int J Immunopathol Pharmacol ; 27(1): 53-67, 2014.
Article in English | MEDLINE | ID: mdl-24674679

ABSTRACT

Class IA phosphatidyl inositol-3 kinases (PI3-K) are important targets in cancer therapy and are essential to immune responses, particularly through costimulation by CD28 and ICOS. Thus, small PI3-K inhibitors are likely candidates to immune intervention. PIK-75 is an efficient inhibitor of the PI3-K p110alpha catalytic subunits that suppresses tumor growth, and its effects on immune and autoimmune responses should be studied. Here, we describe the effect of PIK-75 on different immune parameters in vitro and in vivo. PIK-75 at concentrations commonly used in vitro (≥0.1 μM) inhibited T and B cell activation by Concanavalin A and LPS, respectively, and survival of non-stimulated spleen cells. In naive CD4+ T lymphocytes, PIK-75 induced apoptosis of resting or activated cells that was prevented by caspase inhibitors. At low nanomolar concentrations (≤10 nM), PIK-75 inhibited naive CD4+ T cell proliferation, and IL-2 and IFN-gamma production induced by anti-CD3 plus anti-CD28. In activated CD4+ T blasts costimulated by ICOS, PIK-75 (less than 10 nM) inhibited IFN-gamma, IL-17A, or IL-21 secretion. Furthermore, PIK-75 (20 mg/kg p.o.) suppressed clinical symptoms in ongoing experimental autoimmune encephalomyelitis (EAE) and inhibited MOG-specific responses in vitro. Thus, PIK-75 is an efficient suppressor of EAE, modulating lymphocyte function and survival.


Subject(s)
CD4-Positive T-Lymphocytes/drug effects , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Hydrazones/therapeutic use , Lymphocyte Activation/drug effects , Phosphoinositide-3 Kinase Inhibitors , Sulfonamides/therapeutic use , Animals , Apoptosis/drug effects , CD4-Positive T-Lymphocytes/enzymology , CD4-Positive T-Lymphocytes/pathology , Cells, Cultured , Cytokines/analysis , Dose-Response Relationship, Drug , Encephalomyelitis, Autoimmune, Experimental/enzymology , Encephalomyelitis, Autoimmune, Experimental/pathology , Female , Hydrazones/administration & dosage , Hydrazones/pharmacology , Mice , Mice, Inbred C57BL , Sulfonamides/administration & dosage , Sulfonamides/pharmacology
3.
Acta Biomater ; 6(3): 892-9, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19766743

ABSTRACT

Ordered mesoporous 85SiO(2)-10CaO-5P(2)O(5) bioactive glass (MBG85) is an excellent candidate as a graft for bone tissue regeneration, owing to its excellent textured properties, structural characteristics and crystalline apatite rate formation. To assess MBG85 biocompatibility, different parameters have been evaluated (cell morphology, size/complexity, proliferation, viability, cell cycle, reactive oxygen species content, lactate dehydrogenase release) using human Saos-2 osteoblasts after treatment with either MBG85 extracts or 1% MBG85 directly added to cells. The osteoblast response to MBG85 was compared with L929 fibroblast behaviour after the same treatment. The high cell viability observed and the absence of signs of cell damage in both cell types demonstrates MBG85 biocompatibility. Only a cytostatic effect was observed through the reduction of cell proliferation, related with the initial Ca elution, whereas Si leaching did not result into any negative effect. In vitro lymphocytic proliferation analysis was also carried out with SR.D10 clone after treatment with either MBG85 extracts or culture supernatants of L929 fibroblasts previously treated with 1% MBG85 (cell-conditioned extracts). The absence of modification of in vitro T-cell response underlines the biocompatibility of MBG85 and its potential application in the field of bone and dental grafting.


Subject(s)
Bone Substitutes/chemistry , Bone Transplantation/instrumentation , Fibroblasts/physiology , Glass/chemistry , Lymphocytes/physiology , Osteoblasts/physiology , Animals , Bone Transplantation/methods , Cell Adhesion , Cell Line , Cell Proliferation , Cell Size , Feasibility Studies , Fibroblasts/cytology , Humans , Lymphocytes/cytology , Materials Testing , Mice , Osteoblasts/cytology , Porosity
4.
Inmunología (1987) ; 26(2): 100-107, abr.-jun. 2007. ilus
Article in En | IBECS | ID: ibc-62526

ABSTRACT

Un tema básico en la Inmunología es cómo el Sistema Inmunitariopuede proteger al huésped frente a una extraordinaria variedadde organismos patógenos al mismo tiempo que controla esasrespuestas para que su duración o intensidad no sean perjudicialespara el organismo. Desde hace varios años se han acumuladolos datos que subrayan la importancia de linfocitos T diferenciadosen el timo, denominados linfocitos T reguladores (Treg), enla supresión de las respuestas inmunitarias normales y patológicas,contribuyendo a la tolerancia a los elementos propios y a lahomeostasis inmune. Su papel en el control de la respuesta inmunitariafrente a tumores, alergenos, patógenos e injertos alogeneicosha llamado la atención hacia su potencial uso terapéutico. Sinembargo, para que este potencial pueda convertirse en realidad esprecisa una buena caracterización fenotípica y funcional de estasubpoblación, una tarea que se ha comprobado dificultosa. Así,todavía no están claros muchos puntos acerca de los genes diferenciadoresmaestros de este linaje celular, sus marcadores de superficieespecíficos, o sus mecanismos de supresión.En dos trabajos muy recientes se han descrito las nucleotidasasCD39 y CD73 como marcadores de superficie de las célulasTreg, lo que permite unir la actividad supresora de estas célulascon modelos previos de inmunosupresión en los cuales la adenosinay el AMP cíclico tenían un papel funcional primordial


A key issue in Immunology is how the Immune System managesto achieve its major aim of protecting the host against an extraordinaryvariety of pathogens while, at the same time, controllingresponses whose perduration and intensity might be harmful tothe organism. For some years now, evidence has come out ofthe importance of a thymus-derived T cell subpopulation, called“regulatory” (Treg), able of suppressing physiological and pathologicalresponses, contributing to self tolerance and immunehomeostasis. Its role in controlling immune response to tumours,allergens, pathogens and allogeneic grafts has driven the attentiontowards its therapeutic potential. However, to develop thistherapeutic potential to the full a good phenotypical and functionalcharacterization of this subpopulation is necessary, a taskthat has proven difficult. Thus, many factors still remain obscureconcerning the master differentiation genes of these cells, thespecificity of their surface markers, or their suppressor mechanisms.In two recent papers, the nucleotidases CD39 and CD73 havebeen described as T regulatory cell surface markers, linking thesuppressive activity of these cells with previous immunosuppressormodels in which adenosine and cAMP had functionalrelevance for cellular immunoregulation


Subject(s)
Humans , Biomarkers/analysis , T-Lymphocytes/immunology , Nucleotidases/analysis , Antigens, Surface/analysis , Adenosine/analysis , Cyclic AMP/analysis , 5'-Nucleotidase/analysis
5.
Inmunología (1987) ; 22(4): 385-388, oct. 2003. ilus
Article in Es | IBECS | ID: ibc-37254

ABSTRACT

No disponible


Subject(s)
Humans , Allergy and Immunology
6.
Inmunología (1987) ; 20(4): 196-206, oct. 2001. ilus, tab
Article in En | IBECS | ID: ibc-14860

ABSTRACT

H4/ICOS es una molécula coestimuladora de la familia de CD28, expresada en linfocitos T activados, líneas Th2, algunos timocitos y ciertas células T tumorales. Aquí analizamos sus características estructurales y funcionales, su patrón de expresión, así como las señales implicadas en sus mecanismos coestimuladores. "In vitro", H4/ICOS aumenta la proliferación, la secreción de linfocinas (incluyendo IL-4, IL-5, IL-10, IL-13, GM-CSF, IFNgama , y TNFalfa) y la expresión de CD40L en linfocitos T. Sin coestimulación por H4/ICOS se favorece la secreción de IFN-gamma y disminuye la de linfocinas promotoras de diferenciación Th 2 . "In vivo", H4/ICOS es necesario para el desarrollo de centros germinales y la producción óptima de anticuerpos IgG1, IgG2a e IgE. Además, el bloqueo de H4/ICOS aumenta ciertas reacciones mediadas por células Th1.Estos datos sugieren que H4/ICOS participa en la difere nciación de células Th2, aunque otros datos muestran su importancia en algunas respuestas Th1. H4/ICOS también participa en el desarrollo de enfermedades alérgicas y autoinmunes y en el rechazo de aloinjertos. Los mecanismos señalizadores de H4/ICOS son semejantes a los de CD28, aunque sus diferencias cuantitativas en ciertas vías activadoras y en el momento de la señal pueden producir efectos distintos.En conjunto, H4/ICOS es una molécula que interviene en la respuesta de linfocitos T activados, en la diferenciación y en la fase efectora de las respuestas de linfocitos T, y en la cooperación de células T y B, cuya participación en el control de respuestas inmunitarias normales y patológicas ha de ser analizado con más precisión (AU)


Subject(s)
Animals , Humans , Histones/physiology , Histones/genetics , Histones/immunology , T-Lymphocytes , CD28 Antigens , Cell Differentiation
7.
Eur J Immunol ; 30(5): 1469-79, 2000 May.
Article in English | MEDLINE | ID: mdl-10820395

ABSTRACT

Current models of the TCR / CD3 complex assume that, in mature peripheral T lymphocytes, variability is restricted to the alpha beta (or gamma delta) chains of the TCR heterodimer responsible for antigen recognition, whereas the CD3 polypeptides involved in signal transmission are invariant. Here we show that mouse CD4(+) T lymphocytes and T cell lines are bound with different avidity by anti-CD3 monoclonal antibodies. These findings cannot be accounted for by allelic differences between CD3 chains, by the nature of the TCR chains, or by the ratio of CD3epsilon delta to CD3epsilon gamma chain pairing. Rather, they are linked to heterogeneity of the N-terminal region of CD3epsilon chains, as detected by peptide-specific antibodies. In turn, these differences among CD3epsilon chains correlate with variations in the strength of TCR / CD3 interaction. N-terminal CD3epsilon heterogeneity is not due to alternative splicing mechanisms, but rather involves digestion by metalloproteases, as suggested by reverse transcription-PCR amplification and by the effect of protease inhibitors, respectively. Based on these data, we propose a model linking CD3epsilon N-terminal variability with altered CD3 recognition by monoclonal antibodies and TCR / CD3 interaction. This model suggests the possibility of distinct spatial arrangements of the TCR / CD3 complex.


Subject(s)
CD3 Complex/immunology , Receptors, Antigen, T-Cell/immunology , T-Lymphocytes/immunology , Alleles , Animals , CD3 Complex/genetics , Genetic Variation , Mice
8.
J Immunol ; 164(9): 4533-42, 2000 May 01.
Article in English | MEDLINE | ID: mdl-10779754

ABSTRACT

It is known that certain type I membrane molecules (complement receptors type 1 and 2) belonging to the regulators of complement activation (RCA) family are involved in the regulation of B lymphocyte activation. In contrast, only GPI-anchored RCA molecules (CD55) have been described to be involved in T lymphocyte activation. In this study, we describe a novel function for the mouse RCA type I membrane protein Crry/p65 as a costimulatory molecule in CD4+ T cell activation. This is shown by increased anti-CD3-induced proliferation of CD4+ spleen T lymphocytes in the presence of the Crry/p65-specific mAb P3D2. Furthermore, Ab-induced coligation of Crry/p65 and CD3 favors IL-4 rather than IFN-gamma secretion in these cells. Crry/p65 signaling was also observed regardless of additional Ca2+, protein kinase C, or CD28-mediated costimuli. Analysis of intracellular intermediaries shows that Crry/p65-CD3 coligation enhances certain TCR/CD3-mediated signals, producing increased early tyrosine phosphorylation of many substrates and enhanced activation of the mitogen-activated protein kinase, extracellular signal-related kinase. These data fit well with the association of Crry/p65 with the tyrosine kinase Lck found in T cell lysates. The epitope recognized by the mAb P3D2 interferes with the protective role of Crry/p65 on C3 deposition. The relationship between protective function and costimulation by Crry/p65 is discussed. Our results support a multifunctional role for Crry/p65 in T cells and suggest new links between the natural and adaptive immune responses.


Subject(s)
Lymphocyte Activation/immunology , Receptors, Complement/physiology , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Adjuvants, Immunologic/physiology , Animals , Antibodies, Blocking/pharmacology , Antibodies, Monoclonal/metabolism , Antigens, Surface , Binding Sites, Antibody , CD3 Complex/physiology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Complement Pathway, Alternative/immunology , Female , Humans , K562 Cells , Ligands , Lymphokines/metabolism , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Rats , Rats, Inbred Lew , Receptor-CD3 Complex, Antigen, T-Cell/physiology , Receptors, Cell Surface , Receptors, Complement/antagonists & inhibitors , Receptors, Complement/immunology , Receptors, Complement/metabolism , Receptors, Complement 3b , Signal Transduction/immunology , Spleen/cytology , Spleen/immunology , Spleen/metabolism
9.
Cell Immunol ; 195(2): 96-109, 1999 Aug 01.
Article in English | MEDLINE | ID: mdl-10448009

ABSTRACT

The effect of CD3-CD4 coligation on CD3-mediated activation of normal mouse CD4(+) T lymphocytes has been analyzed in the absence of exogenous lymphokines. If anti-CD3 and anti-CD4 antibodies are adsorbed to culture wells by means of previously adsorbed anti-Ig antibodies (indirect binding), CD3-CD4 coligation inhibits activation measured as cell proliferation or as secretion of IL-2, IL-4, and IFN-gamma. Addition of IL-2, anti-CD28 antibodies, or phorbol esters, but not IL-1, IL-4, or ionomycin, blocked CD4-mediated inhibition and restored the response to levels equal or higher than those of cultures activated by anti-CD3 alone. In contrast, CD3-CD4 coligation by antibodies directly adsorbed to culture wells potentiated anti-CD3-induced activation, either in the absence or in the presence of exogenous costimuli. Similar results were observed when CD4(+) T cells of naive phenotype (CD44(low), CD45RB(high)) were used in the experiments. The analysis of early tyrosine phosphorylation in CD4(+) T cells shows that phosphorylation of many cell substrates is clearly enhanced upon CD3-CD4 coligation using indirectly or directly bound antibodies, yet certain substrates are mainly phosphorylated under inhibitory conditions. Although CD28 ligation does not produce any clear change in the tyrosine phosphorylation pattern in lysates from cells activated by indirectly bound anti-CD3 plus anti-CD4 antibodies, the analysis of active forms of the MAP kinase ERK suggests that downstream signaling pathways involved in IL-2 gene activation can be differentially activated depending on the direct or indirect CD3-CD4 adsorption and CD28 ligation.


Subject(s)
CD3 Complex/metabolism , CD4 Antigens/metabolism , CD4-Positive T-Lymphocytes/immunology , Receptor Aggregation , Receptors, Antigen, T-Cell/antagonists & inhibitors , Signal Transduction , Adsorption , Animals , Antibodies/immunology , CD28 Antigens/metabolism , CD3 Complex/immunology , CD4 Antigens/immunology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/enzymology , CD4-Positive T-Lymphocytes/metabolism , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cells, Cultured , Female , Immune Tolerance/drug effects , Interleukin-2/metabolism , Interleukin-2/pharmacology , Lymphocyte Activation/drug effects , Lymphokines/metabolism , Lymphokines/pharmacology , Male , Mice , Mice, Inbred C3H , Phorbol 12,13-Dibutyrate/pharmacology , Phosphorylation , Phosphotyrosine/metabolism , Receptor Aggregation/drug effects , Receptors, Antigen, T-Cell/metabolism , Signal Transduction/drug effects
10.
Eur J Immunol ; 28(7): 2234-44, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9692893

ABSTRACT

Nucelar NFkappaB was analyzed in murine Th2 cells after stimulation via the TCR pathway. Signals delivered through the TCR/CD3 complex induced active NFkappaB translocation to the nucleus of Th2 cells after a late phase (24 h) of the activation process, which is in contrast to the rapid appearance of nuclear NFkappaB (3 h) in Th1 cells after the same stimulation. The slow kinetic of NFkappaB nuclear uptake in Th2 cells was not accelerated by CD28 triggering or under stimulation with antigen plus antigen-presenting cells. Th1 and Th2 cells were also different in the composition of NFkappaB complexes induced. Whereas in Th1 cells TCR triggering induced the presence of nuclear p50.p65 heterodimers, in Th2 cells the complexes induced were shown to be composed of p65 plus another NFkappaB protein distinct from p50. The delayed NFkappaB induction in Th2 cells was dependent on protein synthesis and the significance of this is discussed.


Subject(s)
NF-kappa B/metabolism , Receptors, Antigen, T-Cell/physiology , Th2 Cells/metabolism , Animals , Cell Line , Cells, Cultured , Cycloheximide/pharmacology , Interleukin-2/physiology , Mice , Protein Biosynthesis , Th1 Cells/metabolism , Transcription, Genetic
11.
J Immunol ; 159(4): 1619-27, 1997 Aug 15.
Article in English | MEDLINE | ID: mdl-9257821

ABSTRACT

We have previously shown that HIV-1 glycoprotein 120 (gp120) induces CD4 association with several molecules on the surface of CD4+ lymphocytes. Since one of these molecules was CD38, involved in lymphocyte/endothelium interaction, this article examines the possibility that gp120/CD4 binding alters CD4+ T cell interaction with vascular endothelium in vitro and in vivo. Cocapping experiments showed that gp120 induced CD4 association with CD38, CD29, CD49d, and CD11a in peripheral blood CD4+ T cells. Two in vitro binding assays were used to evaluate the effect of gp120. A static binding assay, performed at 37 degrees C, evaluated stable interactions mediated by integrins, and a dynamic binding assay, performed at 4 degrees C on a rocking shelf, evaluated weak interactions mediated by constitutively active molecules such as selectins and CD38. Gp120 increased dynamic binding and inhibited static binding to the endothelium of peripheral blood CD4+ T cells and SUPT-1 cells. Binding inhibition with mAbs suggested that the gp120 effect on dynamic binding involved CD38, CD31, and CD49d, whereas the effect on static binding involved CD11a and CD49d. In vivo experiments showed that treatment of 2D4 cells, a CD4- CD8- mouse T cell clone transfected with the human CD4, with gp120 increased their homing into the spleen, intestine, and mesenteric lymph nodes, whereas it decreased homing into peripheral lymph nodes. Alteration of lymphocyte homing may contribute to immune deficiency in HIV-1+ patients by decreasing the probability of an encounter between Ags and lymphocytes and inhibiting the spread of effector lymphocytes into tissues.


Subject(s)
CD4-Positive T-Lymphocytes/physiology , Endothelium, Vascular/cytology , HIV Envelope Protein gp120/physiology , HIV-1/immunology , Animals , Cell Adhesion , Cell Adhesion Molecules/physiology , Humans , Mice
12.
Scand J Immunol ; 45(2): 166-74, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9042429

ABSTRACT

The effect of CD4 expression on the activation threshold of mouse T lymphocytes has been analysed. To do this, the authors studied the response to antigen and other T cell receptor (TCR) ligands in a series of CD4- mutants obtained from the SR.D10 clone. This non-tumour clone spontaneously arose from the Th2 clone D10.G4.1, and characteristically shows a low threshold for antigen activation as well as reactivity to syngeneic antigen presenting cells (APC). Although SR.D10 CD4- mutant cells can be stimulated by antigen, they need higher antigen concentration or more APC than SR.D10 or CD4 transfectants to yield optimal antigen responses. Furthermore, CD4- clones are not activated by syngeneic APC or by clonotypic antibodies. These effects do not correlate with changes in the expression of cell surface molecules implicated in antigen recognition, like TCR/CD3, CD2, LFA-1, or CD45, or with lower p56lck or p59fyn activity in the mutant cells. Since inhibition experiments using anti-CD4 antibodies have previously shown that activation of the CD4+ T cell clone D10.G4.1 by antigen or alloantigens is largely dependent on CD4, our results indicate that activation by antigen-plus self MHC may become CD4-independent if the activation threshold is lowered enough, e.g. in cells like SR.D10. Expression of CD4 further lowers the activation threshold of the cells, allowing the detection of low-affinity TCR reactivities like those directed at self MHC. Moreover, by using anti-TCR/CD3 antibodies, the authors have confirmed the importance of CD4-associated tyrosine kinase activity in early TCR/CD3 signalling in this Th2 cell line, as (1) upon TCR/CD3 ligation, tyrosine phosphorylation is detected only in those CD3 chains co-precipitating with CD4; and (2) CD4 expression is needed for efficient early tyrosine phosphorylation and detectable p56lck-TCR co-precipitation.


Subject(s)
CD4 Antigens/genetics , CD4 Antigens/immunology , Receptors, Antigen, T-Cell/genetics , Signal Transduction/genetics , T-Lymphocytes/immunology , Animals , Antibodies/immunology , Antibodies, Blocking/immunology , Antibodies, Monoclonal , Antigen Presentation , Blotting, Northern , CD2 Antigens/immunology , CD3 Complex/immunology , Cells, Cultured , Clone Cells/immunology , Cloning, Molecular , Flow Cytometry , Gene Expression Regulation , Immunoblotting , Interleukin-1/genetics , Leukocyte Common Antigens/immunology , Lymphocyte Activation , Lymphocyte Function-Associated Antigen-1/immunology , Major Histocompatibility Complex/immunology , Mice , Plasmids , Precipitin Tests , Protein Kinases/metabolism , Recombinant Proteins/immunology , Th2 Cells/immunology , Transfection
13.
Eur J Immunol ; 26(11): 2781-9, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8921969

ABSTRACT

The monoclonal antibody C398.4A was produced by immunizing Armenian hamsters with the mouse T cell clone D10.G4.1. It recognizes a molecule selectively expressed by activated mouse T cells and was named H4. H4 is expressed on the T cell surface about 24 h after activation and peaks at day 7. By contrast, it is not expressed by resting or activated B cells, macrophages, or fibroblasts. It is also expressed by CD4 or CD8 single-positive mature thymocytes. Immunoprecipitation showed that H4 is a disulfide-linked dimer, precipitating as a broad band at about 50-65 kDa under nonreducing conditions and at 25 and 29 kDa under reducing conditions. Deglycosylation of the reduced H4 by N-glycanase gave rise to a single band of about 21 kDa, suggesting that the two chains may be differentially glycosylated forms of the same protein. The H4 expression pattern and biochemical features, together with cross-blocking, co-capping, co-modulation, and immunoprecipitation preclearing experiments showed that H4 is different from other known co-stimulatory molecules such as CD69, CD2, Ly-6, CD25, OX-40, Mac-1 and LFA-1. By in vitro kinase assay, H4 was found to co-precipitate a tyrosine kinase activity that phosphorylated substrates of about 29 and 25 kDa. Co-modulation and co-capping experiments showed that H4 is physically associated with the CD3/T cell receptor. These data suggest that H4 may function as a T cell-specific co-stimulatory molecule and play a role in the T cell response when the activation stimulus is limited either because the antigen is only available in low concentration or has a low agonistic activity.


Subject(s)
Antigens, Differentiation, T-Lymphocyte/physiology , Lymphocyte Activation , Receptor-CD3 Complex, Antigen, T-Cell/physiology , T-Lymphocytes/metabolism , Animals , Antibodies, Monoclonal/immunology , Cricetinae , Cricetulus , Immunophenotyping , Mice , Precipitin Tests , Protein-Tyrosine Kinases/immunology , Signal Transduction/immunology , T-Lymphocytes/immunology
14.
Cell Immunol ; 164(2): 265-78, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7656334

ABSTRACT

A variant of the murine CD4+ T helper cell clone D10.G4.1 (D10) has been isolated and cloned. This line, which we have named "syngeneic-reactive D10", or SR.D10, maintains the I-Ak-restricted specificity for Conalbumin and the allogeneic specificities characteristic of D10 cells. However, it is hyperreactive to TCR-dependent and-independent stimuli, indicating a lower activation threshold than the original D10.G4.1 clone. The hyperreactivity of SR.D10 runs in parallel with the acquisition of a reactive phenotype against syngeneic antigen presenting cells (APCs). As in antigen activation, reactivity to syngeneic APCs can be inhibited by anti-TCR, anti-CD4, or anti-class II monoclonal antibodies. The role of CD4 in this phenomenon is highlighted as "syngeneic reactivity" disappears in CD4- mutants of SR.D10 and is recovered in CD4 transfectants. The expression of several cell surface molecules involved in T cell activation show qualitative and/or quantitative differences between SR.D10 and the original D10. No significant differences in quantity and activity of p56lck and p59fyn were detected between the hyperreactive and the original clone. Our results suggest that high sensitivity to activation, concomitant with expression of CD4, might allow the acquisition of an autoreactive phenotype and confirm the important contribution of coreceptors to determine the activation threshold of the cells. The characteristics of SR.D10 and the possibility of growing them in the presence of interleukins make this cell line a experimental model of great interest for analyzing activation mechanisms in T cells.


Subject(s)
Antigen-Presenting Cells/immunology , CD4-Positive T-Lymphocytes/immunology , Lymphocyte Activation , Animals , Antigens, Differentiation, T-Lymphocyte/metabolism , CD4 Antigens/physiology , Cell Line , Cell Separation , Histocompatibility Antigens Class II/physiology , Immunophenotyping , Mice , Mice, Inbred Strains , Receptors, Antigen, T-Cell/physiology
15.
Eur J Immunol ; 25(5): 1306-11, 1995 May.
Article in English | MEDLINE | ID: mdl-7539755

ABSTRACT

CD4, a lymphocyte surface glycoprotein, serves as co-receptor for antigen with the T cell receptor (TCR). It is also the lymphocyte receptor for HIV by binding the gp120 viral envelope protein. Interaction of gp120 with CD4 is crucial for viral infection, but is not sufficient to allow viral entry into cells. Recombinant gp120 alters CD4+ T cell responsiveness to activation stimuli. To express its co-receptor function fully, CD4 must be laterally associated with the TCR and CD45 to form multi-receptor complexes competent to transduce potent activation signals. Here, we examine the possibility that gp120/CD4 binding alters lateral associations of CD4 with other lymphocyte surface molecules, and that assembly of abnormal multi-molecular complexes is involved in the gp120-induced CD4+ T cell dysfunction and in viral entry. In the absence of gp120, CD4 displayed high association with CD3, CD5, CD45RC, CD25, CD28, CD44, and CD53; weak association with CD2, CD38, CD45RB, CD62L, and CD26; and no association with CD45RA, CD45RO, CD11b, CD11a, CD54, CD7, CD48, CD98, CD59 CD55, HLA class I and class II molecules. Treatment with gp120 significantly increased CD4 association with CD3, CD45RA, CD45RB, CD59, CD38, CD26 and HLA class I, and decreased that with CD45RC. Specificity of these results were assessed at various levels. First, gp120 did not influence lateral associations displayed by other molecules, such as HLA class II. Second, the Leu3 mAb which binds CD4 on a site overlapping the gp120 binding site, did not elicit the same CD4 lateral associations as gp120, and finally, a direct gp120/CD4+ interaction was needed to induce the lateral associations, as shown by the observation that blocking the gp120/CD4 binding by the Leu3 mAb inhibited the gp120-induced associations. These results can be interpreted in several ways gp120/CD4 interaction could trigger an inside-out signal responsible for the associations, or gp120 could induce steric modifications of CD4 that increase its affinity for the associating molecules. Alternatively, these molecules may interact directly with gp120, bridging them with CD4. It is also possible that th e associations may be mediated by additional components, interacting with both gp120 and the associating surface molecule. The last hypothesis is likely for CD59, whose gp120-induced association with CD4 required the presence of serum in the co-capping assay. Since both CD59 and gp120 bind complement, the observed association could be mediated by complement components.


Subject(s)
Antigens, CD/metabolism , Antigens, Surface/metabolism , CD4 Antigens/metabolism , CD4-Positive T-Lymphocytes/immunology , HIV Envelope Protein gp120/pharmacology , HIV-1/immunology , Immunologic Capping/drug effects , Leukocyte Common Antigens/metabolism , Lymphocyte Activation , Receptors, Antigen, T-Cell, alpha-beta/metabolism , T-Lymphocyte Subsets/immunology , Antibodies, Monoclonal/immunology , Antigens, CD/immunology , CD59 Antigens , Complement System Proteins/physiology , Culture Media, Serum-Free , Dipeptidyl Peptidase 4/physiology , HIV Envelope Protein gp120/metabolism , HLA Antigens/immunology , Humans , Leukocyte Common Antigens/immunology , Macromolecular Substances , Membrane Glycoproteins/metabolism , Protein Binding/drug effects , Receptors, Antigen, T-Cell, alpha-beta/immunology , Signal Transduction , T-Lymphocyte Subsets/metabolism
16.
EMBO J ; 13(1): 90-9, 1994 Jan 01.
Article in English | MEDLINE | ID: mdl-7905824

ABSTRACT

Recent observations suggest that the tyrosine kinase p56lck is involved in the transduction of transmembrane signals through the antigen specific T cell receptor (TCR) in CD4+ T cells. By means of in vitro kinase assays, we have found that p56lck coprecipitated with the TCR from lysates of a murine CD4+ T cell line in the absence of TCR-mediated stimuli. Analysis of CD4- mutants and CD4-transfected cells shows that p56lck-TCR association occurred only when CD4 was present. The functional importance of CD4:p56lck-TCR association was demonstrated by low activating potential of rare clonotypic antibodies which did not coprecipitate CD4:p56lck, as well as by total or partial loss of anti-TCR or antigen induced stimulation in CD4- cells, which could be recovered by CD4 transfection. Complementation assays using different anti-TCR antibodies suggest that cross linking of TCR-p56lck:CD4 plus structural changes in the complex are needed for efficient transduction of activating signals through the TCR in these cells.


Subject(s)
CD4 Antigens/metabolism , CD4-Positive T-Lymphocytes/metabolism , Lymphocyte Activation/physiology , Protein-Tyrosine Kinases/metabolism , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Signal Transduction , Animals , CD3 Complex/metabolism , CD4 Antigens/genetics , CD4-Positive T-Lymphocytes/immunology , Cell Line , Flow Cytometry , Lymphocyte Specific Protein Tyrosine Kinase p56(lck) , Mice , Mice, Inbred C3H , Mutation , Precipitin Tests , Transfection
17.
Res Exp Med (Berl) ; 194(4): 261-7, 1994.
Article in English | MEDLINE | ID: mdl-7800935

ABSTRACT

Cancer patients are often treated with biological response modifiers to enhance immunological functions. However, little is known about the actual mechanism of action of many of these substances. Therefore, we were interested in the effect of i.p. treatment with porcine low-molecular-weight spleen peptides, which are used during supportive cancer therapy, on lymphoid cell populations and function in mice. After treatment with 0.5 microgram peptides/kg body weight for 14 consecutive days, lymphokine secretion and the generation of cytotoxic T-cells were significantly enhanced as compared with controls. However, there was no effect on the number of cells or the percentage of cells expressing functional surface markers in secondary lymphoid organs.


Subject(s)
Glycopeptides/immunology , Immunologic Factors/immunology , Phenols/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Antibodies, Monoclonal , Cells, Cultured , Drug Combinations , Injections, Intraperitoneal , Lymphocyte Activation/drug effects , Lymphocyte Subsets/immunology , Lymphokines/metabolism , Male , Mice , Mice, Inbred BALB C , Spleen/cytology
18.
J Immunol ; 148(3): 702-9, 1992 Feb 01.
Article in English | MEDLINE | ID: mdl-1346151

ABSTRACT

Variant lines expressing high and low surface densities of the accessory molecule CD4 have been developed by repeated preparative flow cytometric cell sortings from the murine Th cell clone D10.G4.1 (D10). The high CD4 variant line (D10H) fully maintained the original I-Ak restricted specificity for conalbumin of wild-type D10 cells. In contrast, the low CD4 variant line (D10L) showed a strong autoreactivity to I-Ak carrying stimulator cells alone which was only slightly augmented by addition of conalbumin. Cell surface molecules other than CD4, including TCR, CD3, CD11a, CD2, CD45, CD44, and MHC class I, remained identical on D10H and D10L sublines as on D10 wild-type cells. The possibility that D10L cells had suffered alterations of their TCR-alpha beta was excluded by demonstrating their reactivity with a panel of eight different anti-clonotypic mAb specific for various epitopes of the D10 TCR. By limiting dilution analysis we show that the majority of responding cells of D10L sublines were autoreactive. Although the reactivity for allogeneic I-A also increased as compared with D10H cells, a clear preference for self-I-Ak was maintained so that a true autoreactive phenotype was evident. The results indicate that the surface concentration of CD4 has a decisive influence on self-non-self discrimination of MHC class II-restricted Th cells.


Subject(s)
Autoimmunity , CD4 Antigens/physiology , CD4-Positive T-Lymphocytes/immunology , Histocompatibility Antigens Class II/immunology , Animals , Antigen-Presenting Cells/immunology , Cell Separation , Clone Cells , Genes, MHC Class II , Haplotypes , Lymphocyte Activation , Major Histocompatibility Complex , Mice , Receptors, Antigen, T-Cell/physiology , T-Lymphocytes, Helper-Inducer/immunology
20.
J Immunol Methods ; 129(1): 105-9, 1990 May 08.
Article in English | MEDLINE | ID: mdl-2338494

ABSTRACT

A method for the vectorial radioiodination of CD4 and other membrane proteins having few or no tyrosine residues in the extracytoplasmic domains is described. Incubation of the cells with sulfosuccinimidyl (hydroxyphenyl) propionate (sulfo-SHPP), a water-soluble derivative of the Bolton-Hunter reagent results in the coupling of hydroxyphenyl groups to free amino groups of cell surface proteins and these groups are then vectorially radioiodinated using 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril (Iodogen). The method is highly efficient, gentle, fast, simple, and does not require the previous radiolabelling of the Bolton-Hunter reagent.


Subject(s)
CD4 Antigens/metabolism , Iodine Radioisotopes/metabolism , Animals , Autoradiography , Cell Line , Electrophoresis, Polyacrylamide Gel , Methods , Precipitin Tests , Succinimides , Urea/analogs & derivatives
SELECTION OF CITATIONS
SEARCH DETAIL
...